We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
Read MoreHide Full Article
Shares of Trevi Therapeutics (TRVI - Free Report) surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential treatment for refractory chronic cough (RCC).
The study met its primary endpoint — treatment with Haduvio achieved a statistically significant reduction in the 24-hour cough frequency by 67% from baseline and 57% on a placebo-adjusted basis. Similar efficacy was also seen in Haduvio-treated patients when categorized across severity levels, with a 66% reduction in 24-hour cough frequency in patients with severe cough (≥20 coughs/hour) and a 68% reduction in those with moderate cough (10-19 coughs/hour). These results reinforce the drug’s potential as a broad treatment option, effectively reducing cough frequency regardless of baseline severity.
Haduvio also demonstrated a strong treatment response, with 84% of patients achieving at least a 30% reduction in 24-hour cough frequency from baseline compared with 29% in the placebo group.
Haduvio’s safety profile was also consistent with results from the previously conducted studies. Trevi is also conducting the phase IIb CORAL study, which is evaluating the drug in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Data from this study is expected in the first half of 2025.
TRVI Stock Performance
The above results impressed Wall Street since the efficacy results exceeded the expectations of several analysts. Per Trevi, the RIVER study results make Haduvio the first and only therapy to show a statistically significant reduction in chronic cough across both RCC and IPF patients.
Chronic cough is defined as a cough lasting longer than eight weeks. RCC is a cough that persists despite appropriate treatment of underlying conditions, such as asthma or gastroesophageal reflux disease.
Currently, there are no approved treatments for RCC indication in the United States. Trevi expects that the drug’s potential approval could cater to a broad patient population. The company estimates that about 2-3 million people living in the country are affected by RCC.
Year to date, TRVI shares have surged more than 47% compared with the industry’s 7% growth.
Image Source: Zacks Investment Research
Other Players Developing Drugs for RCC
Apart from Trevi, GSK plc (GSK - Free Report) is evaluating its own investigational chronic cough drug in late-stage development. The drug named camlipixant was added by GSK after it acquired Bellus Health in 2023. GSK expects to launch its RCC drug commercially in 2026.
Another company that was once ahead in the RCC drug race was Merck (MRK - Free Report) , whose chronic cough drug, gefapixant, received two complete response letters (CRL) from the FDA. While the agency issued the first CRL in 2022 requesting Merck to submit additional information regarding the drug’s efficacy, the second CRL was issued in 2023, which concluded that the data submitted by Merck did not provide sufficient evidence proving the drug’s clinical benefit. After receiving the second CRL, Merck decided to end this drug’s development.
Image: Bigstock
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
Shares of Trevi Therapeutics (TRVI - Free Report) surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential treatment for refractory chronic cough (RCC).
The study met its primary endpoint — treatment with Haduvio achieved a statistically significant reduction in the 24-hour cough frequency by 67% from baseline and 57% on a placebo-adjusted basis. Similar efficacy was also seen in Haduvio-treated patients when categorized across severity levels, with a 66% reduction in 24-hour cough frequency in patients with severe cough (≥20 coughs/hour) and a 68% reduction in those with moderate cough (10-19 coughs/hour). These results reinforce the drug’s potential as a broad treatment option, effectively reducing cough frequency regardless of baseline severity.
Haduvio also demonstrated a strong treatment response, with 84% of patients achieving at least a 30% reduction in 24-hour cough frequency from baseline compared with 29% in the placebo group.
Haduvio’s safety profile was also consistent with results from the previously conducted studies. Trevi is also conducting the phase IIb CORAL study, which is evaluating the drug in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Data from this study is expected in the first half of 2025.
TRVI Stock Performance
The above results impressed Wall Street since the efficacy results exceeded the expectations of several analysts. Per Trevi, the RIVER study results make Haduvio the first and only therapy to show a statistically significant reduction in chronic cough across both RCC and IPF patients.
Chronic cough is defined as a cough lasting longer than eight weeks. RCC is a cough that persists despite appropriate treatment of underlying conditions, such as asthma or gastroesophageal reflux disease.
Currently, there are no approved treatments for RCC indication in the United States. Trevi expects that the drug’s potential approval could cater to a broad patient population. The company estimates that about 2-3 million people living in the country are affected by RCC.
Year to date, TRVI shares have surged more than 47% compared with the industry’s 7% growth.
Image Source: Zacks Investment Research
Other Players Developing Drugs for RCC
Apart from Trevi, GSK plc (GSK - Free Report) is evaluating its own investigational chronic cough drug in late-stage development. The drug named camlipixant was added by GSK after it acquired Bellus Health in 2023. GSK expects to launch its RCC drug commercially in 2026.
Another company that was once ahead in the RCC drug race was Merck (MRK - Free Report) , whose chronic cough drug, gefapixant, received two complete response letters (CRL) from the FDA. While the agency issued the first CRL in 2022 requesting Merck to submit additional information regarding the drug’s efficacy, the second CRL was issued in 2023, which concluded that the data submitted by Merck did not provide sufficient evidence proving the drug’s clinical benefit. After receiving the second CRL, Merck decided to end this drug’s development.
Trevi Therapeutics, Inc. Price
Trevi Therapeutics, Inc. price | Trevi Therapeutics, Inc. Quote
TRVI’s Zacks Rank
Trevi currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.